Last reviewed · How we verify
Aleph influenza vaccine
Aleph influenza vaccine stimulates the immune system to produce antibodies and cellular immunity against influenza virus strains.
Aleph influenza vaccine stimulates the immune system to produce antibodies and cellular immunity against influenza virus strains. Used for Influenza prevention in adults and children.
At a glance
| Generic name | Aleph influenza vaccine |
|---|---|
| Sponsor | Beijing Center for Disease Control and Prevention |
| Drug class | vaccine |
| Modality | Biologic |
| Therapeutic area | Immunology |
| Phase | FDA-approved |
Mechanism of action
As an influenza vaccine, it contains inactivated or attenuated influenza virus antigens that train the adaptive immune system to recognize and respond to circulating influenza strains. Upon exposure to wild-type influenza virus, vaccinated individuals mount a faster and more robust immune response, reducing infection severity and transmission risk.
Approved indications
- Influenza prevention in adults and children
Common side effects
- Injection site pain or erythema
- Myalgia
- Headache
- Low-grade fever
Key clinical trials
- Study on Heterologous Prime-boost of Recombinant COVID-19 Vaccine (Ad5 Vector) and RBD-based Protein Subunit Vaccine (PHASE4)
- Safety and Immunogenicity Study of Aleph Inactivated Split Influenza Vaccine (PHASE4)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- Aleph influenza vaccine CI brief — competitive landscape report
- Aleph influenza vaccine updates RSS · CI watch RSS
- Beijing Center for Disease Control and Prevention portfolio CI